GenSight Biologics S.A. (EPA:SIGHT)
0.0870
-0.0010 (-1.14%)
Dec 16, 2025, 10:19 AM CET
GenSight Biologics Employees
GenSight Biologics had 16 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€72,692
Profits / Employee
€1,163,077
Market Cap
16.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 0 | - |
| Dec 31, 2023 | 16 | -29 | -64.44% |
| Dec 31, 2022 | 45 | 7 | 18.42% |
| Dec 31, 2021 | 38 | 13 | 52.00% |
| Dec 31, 2020 | 25 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| emeis Société anonyme | 83,494 |
| Sanofi | 82,878 |
| Eurofins Scientific SE | 62,696 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 9,901 |
GenSight Biologics News
- 13 days ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire
- 4 weeks ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million • news - Onvista
- 6 weeks ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire
- 2 months ago - GenSight Biologics Reports Cash Position as of September 30, 2025 - Business Wire
- 2 months ago - GenSight Biologics Reports Interim Financial Results for the First Half of 2025 - Business Wire
- 3 months ago - GenSight Biologics Postpones Release of 2025 Half-Year Financial Results - Business Wire
- 5 months ago - GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy - Business Wire
- 5 months ago - GenSight Biologics Reports Cash Position as of June 30, 2025 - Business Wire